VIRTUOZZO
Virtuozzo, a global leader in high-efficiency virtualization and hyperconverged software solutions, has announced the availability of its newest product, Virtuozzo Hybrid Cloud . The solution enables Managed Service Providers (MSPs) and Cloud Service Providers (CSP) to design, build and sell modern cloud services to customers quickly and more cost-effectively than traditional hyperscalers.
The cloud infrastructure market continues to experience strong growth as businesses become increasingly more dependent on cloud-based resources. This evolution presents an opportunity for service providers to carve out an alternative to the often complex and expensive traditional cloud providers. According to Liam Eagle, Research Director, 451 Research, a part of S&P Global Market Intelligence, “As the breadth of organizations seeking cloud solutions continues to grow, a gap in the skills necessary to navigate the complexities of the most advanced cloud platforms is a common limitation. This presents an opportunity for the alternative vendors to solidify the role of their services as delivering the core value proposition of cloud in a simpler, more digestible and often lower-cost configuration.” 1
Virtuozzo Hybrid Cloud was created to help service providers address this demand. The company’s new product offers MSPs and CSPs an alternative, fully managed cloud solution that ensures clear SLAs and 24/7 production support, allowing service providers to focus on value-added services and project development rather than infrastructure maintenance and management.
Virtuozzo Hybrid Cloud is one of the only hybrid cloud solutions exclusively for MSPs and CSPs. It offers Infrastructure as a Service (IaaS), Platform as a Service (PaaS), Load Balancer as a Service (LBaaS), Storage as a Service (SaaS), and other cloud services in multiple locations worldwide.
Service providers can buy cloud resources directly from Virtuozzo by connecting any Open Stack compatible cloud management platform such as CloudBlue Connect, HostBill, WHMCS, Fleio, or from Virtuozzo Hybrid Cloud distributors.
“Over the past year and a half, we have seen a lot of demand from our existing service provider partners for a solution that enables them to offer infrastructure solutions. We designed Virtuozzo Hybrid Cloud to address this need while offering more than 30% savings over comparable solutions. We are thrilled to bring a turnkey solution to the market that helps MSPs and CSPs open new opportunities and drive customer growth for years to come. We are excited to innovate and grow together with our partners,” remarks Ahmed Amni, Director of Sales, EMEA.
Virtuozzo Hybrid Cloud is built on Virtuozzo Hybrid Infrastructure, a best-in-class hyperconverged infrastructure (HCI) solution. Virtuozzo Hybrid Infrastructure provides service providers with cost-effective, easy-to-manage hyperconverged infrastructure that optimizes hardware utilization, lowers total cost of ownership, and delivers high server performance and availability. Secure by design, Virtuozzo Hybrid Infrastructure combines compute, storage, and networking services with advanced analytics and monitoring in a single, hardware-agnostic solution.
Virtuozzo Hybrid Cloud is available to service providers throughout Europe today, with global availability rolling out quickly. Pricing is based on either a Pay-as-You-Go model or on a reservation-based model, which extends additional cost savings to partners. To learn more about partnership opportunities or to view a product demo visit the company’s website .
About Virtuozzo
Virtuozzo is a leading, global provider of hybrid virtualization, storage and cloud enablement software solutions. The company’s software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The company provides software solutions and services to over 450 service providers, ISVs, and enterprises worldwide to enable over 500 thousand virtual environments, running mission-critical cloud workloads. A significant force in the opensource community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU and the Linux kernel. Learn more www.virtuozzo.com .
1 451 Research, Demand and opportunity in the alternative cloud provider market , January 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005247/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom